Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults-Reference-Cited by-同舟云学术

Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults

Published:2022-12-20 Issue:12 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lodise Thomas P.¹^ORCID,O’Donnell J. Nicholas¹^ORCID,Balevic Stephen²,Liu Xing²,Gu Kenan³,George Jomy³,Raja Shruti⁴^ORCID,Guptill Jeffrey T.⁴,Zaharoff Smitha²,Schwager Nyssa²,Fowler Vance G.²^ORCID,Wall Alison⁵^ORCID,Wiegand Katherine⁵,Chambers Henry F.⁶^ORCID,

Affiliation:

1. Albany College of Pharmacy and Health Sciences, Albany, New York, USA

2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA

3. Office of Regulatory Affairs (ORA), Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA

4. Duke Early Phase Clinical Research Unit, Duke University School of Medicine, Durham, North Carolina, USA

5. The Emmes Company, Rockville, Maryland, USA

6. University of California, San Francisco, and San Francisco General Hospital, San Francisco, California, USA

Abstract

Scant pharmacokinetic (PK) data are available on ceftazidime-avibactam (CZA) and aztreonam (ATM) in combination, and it is unknown if CZA-ATM exacerbates alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations relative to ATM alone. This phase 1 study sought to describe the PK of CZA-ATM and assess the associations between ATM exposures and ALT/AST elevations.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00936-22

Reference58 articles.

1. In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015

2. The global epidemiology of carbapenemase-producing Enterobacteriaceae

3. The emergence and implications of metallo-β-lactamases in Gram-negative bacteria